This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dogs of the Dow's 'Mutts' Have No Bite

Stocks in this article: PFE MRK JNJ ABT BAX

NEW YORK ( TheStreet) -- At the beginning of every year, proponents of the "Dogs of the Dow" investment strategy trot out the 10 highest-yielding stocks in the Dow Jones Industrial Average and suggest buying them as a means of beating the market.

Although every dog has its day, there are always some perennial losers in the pack, in terms of return on investment, so strictly hewing to that strategy has its faults.

For example, 2010 was the first year since 2006 when the Dogs' return outdid that of the Dow, excluding dividends. The group has only done it three times in the past eight years, and only in 2006, when the Dogs returned 30% vs. the 19% of the Dow, was it a blowout victory.

But 2010 was also a very strong year for the Dow Dogs' strategy, as the group returned an average 16.3%, while the blue-chip index returned 11%.

The average 3.87% yield the class of 2010 paid in dividends also makes the Dogs of the Dow strategy worth considering.

But every year there are a couple of mutts among the Dogs that investors would have best avoided. Lately, they've been from the health care sector, one of the poorest-performing groups in 2010 with a return of 6.5%, which is next to last out of all investment sectors.

In 2010, the Dogs were held back by pharmaceutical giants Pfizer (PFE), down 3.7% on the year, and Merck (MRK), off 1.4%. A newcomer to the Dogs that's going on the list for 2011, health care products conglomerate Johnson & Johnson (JNJ), was right in step, losing 4% in 2010.

And yet analysts are fond of these stocks because of their long-term prospects, which are built on the idea that a glut of baby boomers, now edging into retirement, will gobble an ever-increasing number of drugs as they age. The elderly currently account for about one-third of drug industry sales.

So we decided to look at the prospects for those three companies, as well as two of their competitors that face similar challenges.

1 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs